BR112017027798A2 - compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos - Google Patents

compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos

Info

Publication number
BR112017027798A2
BR112017027798A2 BR112017027798-0A BR112017027798A BR112017027798A2 BR 112017027798 A2 BR112017027798 A2 BR 112017027798A2 BR 112017027798 A BR112017027798 A BR 112017027798A BR 112017027798 A2 BR112017027798 A2 BR 112017027798A2
Authority
BR
Brazil
Prior art keywords
diseases
histone deacetylase
inhibitor
pharmaceutical composition
same
Prior art date
Application number
BR112017027798-0A
Other languages
English (en)
Other versions
BR112017027798B1 (pt
Inventor
Lee Jaekwang
Han Younghue
Kim Yuntae
Min Jaeki
BAE Miseon
Kim Dohoon
Jin Seokmin
Kyung Jangbeen
Original Assignee
Chong Kun Dang Pharmaceutical Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp. filed Critical Chong Kun Dang Pharmaceutical Corp.
Publication of BR112017027798A2 publication Critical patent/BR112017027798A2/pt
Publication of BR112017027798B1 publication Critical patent/BR112017027798B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Abstract

a presente invenção se refere a compostos inovadores que têm atividade inibitória de histona desacetilase 6 (hdac6), estereoisômeros dos mesmos ou sais farmaceuticamente aceitáveis dos mesmos, o uso dos mesmos para a preparação de medicamentos terapêuticos, composições farmacêuticas que contém os mesmos, um método para o tratamento de doenças com o uso da composição e métodos para a preparação dos compostos inovadores. os compostos inovadores, estereoisômeros dos mesmos ou sais farmaceuticamente aceitáveis dos mesmos de acordo com a presente invenção têm atividade inibitória de histona desacetilase (hdac) e são eficazes para a prevenção ou tratamento de doenças mediadas por hdac6, incluindo doenças infecciosas; neoplasmas; doenças endócrinas, nutricionais e metabólicas; distúrbios mentais e comportamentais; doenças neurológicas; doenças dos olhos e anexos; doenças cardiovasculares; doenças respiratórias; doenças digestivas; doenças da pele e tecido subcutâneo; doenças do sistema musculoesquelético e tecido conjuntivo; ou malformações congênitas, deformações e anormalidades cromossômicas.
BR112017027798-0A 2015-07-27 2016-07-27 Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos BR112017027798B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150106177 2015-07-27
KR10-2015-0106177 2015-07-27
PCT/KR2016/008218 WO2017018805A1 (en) 2015-07-27 2016-07-27 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Publications (2)

Publication Number Publication Date
BR112017027798A2 true BR112017027798A2 (pt) 2018-08-28
BR112017027798B1 BR112017027798B1 (pt) 2023-12-19

Family

ID=57885712

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017027798-0A BR112017027798B1 (pt) 2015-07-27 2016-07-27 Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos

Country Status (22)

Country Link
US (1) US10464911B2 (pt)
EP (1) EP3328844B1 (pt)
JP (1) JP6538266B2 (pt)
KR (1) KR101799005B1 (pt)
CN (1) CN107980040B (pt)
AU (1) AU2016299486B2 (pt)
BR (1) BR112017027798B1 (pt)
CA (1) CA2987570C (pt)
DK (1) DK3328844T3 (pt)
ES (1) ES2774510T3 (pt)
HK (1) HK1251549A1 (pt)
HR (1) HRP20200280T1 (pt)
HU (1) HUE048534T2 (pt)
MX (1) MX2017017090A (pt)
MY (1) MY194018A (pt)
NZ (1) NZ736432A (pt)
PH (1) PH12017501939A1 (pt)
PL (1) PL3328844T3 (pt)
PT (1) PT3328844T (pt)
RU (1) RU2695227C9 (pt)
TW (1) TWI694074B (pt)
WO (1) WO2017018805A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291810B1 (en) 2015-05-07 2022-08-10 CHDI Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
EA035592B1 (ru) 2015-05-07 2020-07-13 Сиэйчдиай Фаундэйшн, Инк. Ингибиторы деацетилаз гистонов и композиции и способы их применения
RU2697665C1 (ru) 2015-07-27 2019-08-16 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфонамида в качестве ингибиторов деацетилазы гистонов 6 и фармацевтическая композиция, содержащая их
AU2016299486B2 (en) 2015-07-27 2019-08-01 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
JP6559325B2 (ja) 2015-07-27 2019-08-14 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾールアミド誘導体化合物及びこれを含有する薬剤学的組成物，
HUE057544T2 (hu) 2015-08-04 2022-05-28 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazol-származék vegyületek mint hiszton deacetiláz 6 inhibitorok, és ezeket tartalmazó gyógyszerkészítmények
US10494355B2 (en) 2015-10-12 2019-12-03 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN111032651A (zh) * 2017-07-31 2020-04-17 武田药品工业株式会社 杂环化合物
KR102059027B1 (ko) * 2018-01-12 2019-12-24 주식회사 비엔에이치리서치 Hdac6 억제제를 유효성분으로 포함하는 가려움증 예방 또는 치료용 약제학적 조성물
KR102316234B1 (ko) * 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
WO2020158762A1 (ja) 2019-01-30 2020-08-06 武田薬品工業株式会社 複素環化合物
EP3956324B1 (en) 2019-04-17 2024-02-21 Quimatryx, S.L. 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors
TW202126643A (zh) 2019-09-27 2021-07-16 日商武田藥品工業股份有限公司 雜環化合物
CR20220325A (es) 2019-12-20 2022-08-19 Tenaya Therapeutics Inc Fluoroalquil-oxadiazoles y sus usos
KR102537616B1 (ko) * 2020-02-25 2023-05-26 주식회사 종근당 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
CN116133658A (zh) * 2020-07-14 2023-05-16 株式会社 钟根堂 作为组蛋白去乙酰酶6抑制剂的新化合物及包含该化合物的药物组合物
EP4192830A1 (en) 2020-08-07 2023-06-14 Italfarmaco SpA 2-(4-((5-(benzo[b]thiophen-3-yl)-1h-tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (hdac6) for use in treating e.g. peripheral neuropathy
IL307883A (en) 2021-04-23 2023-12-01 Tenaya Therapeutics Inc HDAC6 inhibitors for use in the treatment of dilated myocardial disease
EP4333841A1 (en) * 2021-05-04 2024-03-13 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
WO2024017897A1 (en) 2022-07-19 2024-01-25 Italfarmaco S.P.A. 1,3,4-oxadiazole derivatives as selective histone deacetylase 6 inhibitors
WO2024033293A1 (en) 2022-08-08 2024-02-15 Italfarmaco S.P.A. Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors
KR20240035172A (ko) * 2022-09-08 2024-03-15 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도
WO2024079682A1 (en) * 2022-10-14 2024-04-18 Chong Kun Dang Pharmaceutical Corp. Sulfoximine compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871753A (en) 1986-12-12 1989-10-03 Ciba-Geigy Corporation 3-Phenyl-5-trifluoromethyl-1,2,4-oxadiazole compounds which are useful pesticides
KR100265385B1 (ko) 1998-02-27 2000-11-01 윤여표 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
BR0213129A (pt) 2001-10-03 2004-08-10 Pharmacia Corp Pró-drogas de compostos policìclicos substituìdos, úteis para inibição seletiva da cascata da coagulação
MXPA04005927A (es) 2001-12-20 2004-11-01 Squibb Bristol Myers Co Derivados de alfa-(n-sulfonamido)acetamida como inhibidores del peptido beta-amiloideo.
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
AU2006278397B2 (en) 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
WO2007032445A1 (ja) 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
MX2008011857A (es) 2006-03-23 2008-12-15 Prolysis Ltd Agentes antibacterianos.
TW200808707A (en) * 2006-06-14 2008-02-16 Methylgene Inc Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
EP1878730A1 (en) 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same
WO2008073509A2 (en) 2006-12-11 2008-06-19 Genentech, Inc. Compositions and methods for treating a neoplasm
WO2009010479A2 (en) 2007-07-13 2009-01-22 Euroscreen S.A. Heterocyclic methylene piperidine derivatives and their use
KR100903743B1 (ko) 2007-08-28 2009-06-19 전병태 소화기계 질환개선 및 예방용 식품 조성물
CA2703718A1 (en) 2007-11-02 2009-05-07 Tammy Mallais Inhibitors of histone deacetylase
KR101561860B1 (ko) 2007-11-02 2015-10-20 모멘타 파머슈티컬스 인코포레이티드 비항응고성 다당류 조성물
JP5665740B2 (ja) * 2008-07-23 2015-02-04 プレジデント アンド フェローズ オブ ハーバード カレッジ デアセチラーゼ阻害剤およびその使用
EP2421528A4 (en) 2009-04-20 2012-10-17 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
JP2011008205A (ja) 2009-05-27 2011-01-13 Fujifilm Corp 二軸性光学異方性膜を作製するための組成物
US8431538B2 (en) 2009-07-22 2013-04-30 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods of using same
JP2013517281A (ja) 2010-01-13 2013-05-16 テンペロ、ファーマシューティカルズ、インコーポレイテッド 化合物及び方法
AU2011205283B2 (en) 2010-01-13 2014-07-10 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2526093B1 (en) 2010-01-22 2016-08-17 Acetylon Pharmaceuticals, Inc. Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
AU2011219480A1 (en) 2010-02-25 2012-10-11 Piramal Enterprises Limited Oxadiazole compounds, their preparation and use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
MX2012013081A (es) 2010-05-12 2013-05-09 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
RU2601550C2 (ru) 2010-12-09 2016-11-10 Вокхардт Лимитед Кетолидные соединения
KR101262870B1 (ko) 2011-01-28 2013-05-09 환인제약 주식회사 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물
US9056843B2 (en) 2011-07-08 2015-06-16 Novartis Ag Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
US9512083B2 (en) 2011-07-20 2016-12-06 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
WO2013041407A1 (en) 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors
WO2013052110A1 (en) 2011-10-03 2013-04-11 The Trustees Of Columbia University In The City Of New York Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
WO2013066835A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066833A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
WO2013066838A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066839A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
MX2014006409A (es) 2011-11-28 2014-07-30 Novartis Ag Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
EP2785720B1 (en) 2011-11-29 2017-08-09 Nanjing Allgen Pharma Co. Ltd. Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents
CA2866707A1 (en) 2012-03-07 2013-09-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Selective histone deactylase 6 inhibitors
RS57559B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,3,4-oksadiazol i 1,3,4-tiadiazol derivativi kao imunomodulatori
CN105940001B (zh) * 2013-12-12 2018-02-06 株式会社钟根堂 作为选择性组蛋白脱乙酰酶(hdac)抑制剂的新型氮杂吲哚衍生物及包含其的药物组合物
CN104744446B (zh) 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
KR101909092B1 (ko) 2014-11-24 2018-10-17 (주) 메디프론디비티 바닐로이드 수용체 리간드 ii로서의 치환된 옥사졸계 및 싸이아졸계 카복스아미드 및 우레아 유도체
CN106349451B (zh) 2015-07-14 2020-11-13 罗门哈斯公司 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法
AU2016299486B2 (en) 2015-07-27 2019-08-01 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
JP6559325B2 (ja) * 2015-07-27 2019-08-14 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾールアミド誘導体化合物及びこれを含有する薬剤学的組成物，
RU2697665C1 (ru) * 2015-07-27 2019-08-16 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфонамида в качестве ингибиторов деацетилазы гистонов 6 и фармацевтическая композиция, содержащая их
HUE057544T2 (hu) 2015-08-04 2022-05-28 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazol-származék vegyületek mint hiszton deacetiláz 6 inhibitorok, és ezeket tartalmazó gyógyszerkészítmények
US10494355B2 (en) 2015-10-12 2019-12-03 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
HK1251549A1 (zh) 2019-02-01
AU2016299486A1 (en) 2017-11-09
HUE048534T2 (hu) 2020-07-28
EP3328844A4 (en) 2018-12-19
TWI694074B (zh) 2020-05-21
CN107980040B (zh) 2021-11-26
WO2017018805A1 (en) 2017-02-02
KR101799005B1 (ko) 2017-11-17
AU2016299486B2 (en) 2019-08-01
JP6538266B2 (ja) 2019-07-03
CA2987570A1 (en) 2017-02-02
RU2695227C1 (ru) 2019-07-22
CN107980040A (zh) 2018-05-01
MY194018A (en) 2022-11-08
JP2018521092A (ja) 2018-08-02
DK3328844T3 (da) 2020-03-02
KR20170013186A (ko) 2017-02-06
PH12017501939B1 (en) 2018-03-19
NZ736432A (en) 2019-01-25
US10464911B2 (en) 2019-11-05
US20180230113A1 (en) 2018-08-16
RU2695227C9 (ru) 2020-03-04
EP3328844B1 (en) 2019-11-27
ES2774510T3 (es) 2020-07-21
TW201712007A (zh) 2017-04-01
BR112017027798B1 (pt) 2023-12-19
CA2987570C (en) 2021-06-15
PH12017501939A1 (en) 2018-03-19
PL3328844T3 (pl) 2020-07-27
EP3328844A1 (en) 2018-06-06
PT3328844T (pt) 2020-03-04
HRP20200280T1 (hr) 2020-05-29
MX2017017090A (es) 2018-12-11

Similar Documents

Publication Publication Date Title
BR112017027798A2 (pt) compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR112018002304A8 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR112018001720A2 (pt) compostos de derivado de 1,3,4-oxadiazol sulfonamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
PH12018500773B1 (en) Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
PH12018500162B1 (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
PH12016501735A1 (en) Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
BR112012028091A2 (pt) composições farmacêuticas compreendendo pioglitazona e linagliptina
BR112021023640A2 (pt) Compostos de derivado de 1,3,4-oxadiazol homoftalimida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR112021023770A2 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR112017008734A2 (pt) acelerador de produção de proteína tau e agente preventivo ou terapêutico e composição alimentícia preventiva ou terapêutica para doenças causadas por deficiência de proteína tau
JP2017008001A5 (pt)
BR112018067663A2 (pt) compostos derivados de sulfamato, processos para preparação dos mesmos e seus usos
BR112018070521A2 (pt) processo para preparação de formulações sólidas de mesalazina
BR112021024054A2 (pt) Composições farmacêuticas de combinação de dose fixa de liberação imediata, seus métodos e usos.
TH1801000467A (th) สารประกอบอนุพันธ์1,3,4-ออกซาไดอะโซลซัลโฟนาไมด์ที่เป็นแบบตัวยับยั้งฮิสโตนดีอะเซทิเลส6และส่วนประกอบทางเภสัชกรรมที่ประกอบด้วยสารเดียวกันนั้น
EA201800310A1 (ru) Фармацевтическая композиция
EA201600336A2 (ru) Лекарственное средство для профилактики и лечения заболеваний головного мозга и способ лечения заболеваний головного мозга
IN2014MU01184A (pt)
IN2014MU01185A (pt)
TH154747A (th) สารประกอบเฮเทอโรไซคลิกที่เหมาะสมสำหรับการรักษาภาวะไขมันในเลือดสูง

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/07/2016, OBSERVADAS AS CONDICOES LEGAIS